ResearcherHeidelberg UniversityNo recent work listed

Li Liu

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0002-2178-9237; OpenAlex author ID A5100418786. Sources: OpenAlex.

Their work

Papers: 1
Trials: 0
Grants: 0
Labs led: 0
Collaborators: 4

Papers, trials and grants by year

2022: 1 paper

Papers 1

Nanosilver inhibits the progression of pancreatic cancer by inducing a paraptosis-like mixed type of cell death. Co-author DOI 10.1016/j.biopha.2022.113511 ↗

Closest collaborators

The 4 strongest of 4 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

Xuefeng An · 1 shared paper, 2022 · strength 0.16
- Paper Nanosilver inhibits the progression of pancreatic cancer by inducing a paraptosis-like mixed type of cell death. DOI 10.1016/j.biopha.2022.113511 ↗
Michael Schaefer · 1 shared paper, 2022 · strength 0.16
- Paper Nanosilver inhibits the progression of pancreatic cancer by inducing a paraptosis-like mixed type of cell death. DOI 10.1016/j.biopha.2022.113511 ↗
Bin Yan · 1 shared paper, 2022 · strength 0.16
- Paper Nanosilver inhibits the progression of pancreatic cancer by inducing a paraptosis-like mixed type of cell death. DOI 10.1016/j.biopha.2022.113511 ↗
Ingrid Herr · 1 shared paper, 2022 · strength 0.16
- Paper Nanosilver inhibits the progression of pancreatic cancer by inducing a paraptosis-like mixed type of cell death. DOI 10.1016/j.biopha.2022.113511 ↗

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.